Literature DB >> 18472017

Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis.

Elizabeth A Grimm1, Julie Ellerhorst, Chi-Hui Tang, Suhendan Ekmekcioglu.   

Abstract

Human melanoma tumors cells are known to express the enzyme, inducible nitric oxide synthase (iNOS), which is responsible for cytokine induced nitric oxide (NO) production during immune responses. This constitutive expression of iNOS in many patients' tumor cells, as well as its strong association with poor patient survival, have led to the consideration of iNOS as a molecular marker of poor prognosis, as well as a possible target for therapy. The expression of iNOS in patient tumors was found to associate with nitrotyrosine, COX2, pSTAT3, and arginase. Using human melanoma patients' samples as well as cell lines, we have further evidence supporting intracellular NO production by detection of nitrotyrosine and also by use of DAF-2DA staining. Experiments were performed to scavenge the endogenous NO (with c-PTIO) resulting in melanoma cell growth inhibition; this was restored with SIN-1 (NO and O2-donor) providing data to support a functional role of this gas. Our goal is to understand the aberrant biology leading to this curious phenomenon, and to regulate it in favor of patient treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472017      PMCID: PMC2577016          DOI: 10.1016/j.niox.2008.04.009

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  10 in total

1.  Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes.

Authors:  F L Meyskens; S E McNulty; J A Buckmeier; N B Tohidian; T J Spillane; R S Kahlon; R I Gonzalez
Journal:  Free Radic Biol Med       Date:  2001-09-15       Impact factor: 7.376

2.  Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.

Authors:  S Ekmekcioglu; J Ellerhorst; C M Smid; V G Prieto; M Munsell; A C Buzaid; E A Grimm
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

3.  Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells.

Authors:  H J Garbán; B Bonavida
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

4.  Antiapoptotic role of endogenous nitric oxide in human melanoma cells.

Authors:  O Salvucci; M Carsana; I Bersani; G Tragni; A Anichini
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

5.  Nitric oxide synthase reduces nitrite to NO under anoxia.

Authors:  A F Vanin; L M Bevers; A Slama-Schwok; E E van Faassen
Journal:  Cell Mol Life Sci       Date:  2007-01       Impact factor: 9.261

6.  Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines.

Authors:  Chi-Hui Tang; Elizabeth A Grimm
Journal:  J Biol Chem       Date:  2003-10-23       Impact factor: 5.157

7.  Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells.

Authors:  Mingzhong Zheng; Suhendan Ekmekcioglu; Eugene T Walch; Chi-Hui Tang; Elizabeth A Grimm
Journal:  Melanoma Res       Date:  2004-06       Impact factor: 3.599

8.  Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.

Authors:  C M Anderson; A C Buzaid; J Sussman; J J Lee; F Ali-Osman; P G Braunschweiger; C Plager; A Bedikian; N Papadopoulos; O Eton; S S Legha; E A Grimm
Journal:  Melanoma Res       Date:  1998-04       Impact factor: 3.599

9.  Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

Authors:  Omar Eton; Sewa S Legha; Agop Y Bedikian; J Jack Lee; Antonio C Buzaid; Cynthia Hodges; Sigrid E Ring; Nicholas E Papadopoulos; Carl Plager; Mary Jo East; Feng Zhan; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

10.  Tumor iNOS predicts poor survival for stage III melanoma patients.

Authors:  Suhendan Ekmekcioglu; Julie A Ellerhorst; Victor G Prieto; Marcella M Johnson; Lyle D Broemeling; Elizabeth A Grimm
Journal:  Int J Cancer       Date:  2006-08-15       Impact factor: 7.396

  10 in total
  21 in total

Review 1.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Authors:  Elizabeth A Grimm; Andrew G Sikora; Suhendan Ekmekcioglu
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

Review 2.  Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance.

Authors:  Elizabeth A Grimm
Journal:  Crit Rev Oncog       Date:  2016

3.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

4.  Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.

Authors:  Kalpana Mujoo; Vladislav G Sharin; Emil Martin; Byung-Kwon Choi; Courtney Sloan; Lubov E Nikonoff; Alexander Y Kots; Ferid Murad
Journal:  Nitric Oxide       Date:  2009-12-03       Impact factor: 4.427

5.  Src kinase-mediated phosphorylation stabilizes inducible nitric-oxide synthase in normal cells and cancer cells.

Authors:  Alexey Tyryshkin; F Murat Gorgun; Elmoataz Abdel Fattah; Tuhina Mazumdar; Lavannya Pandit; Shenyan Zeng; N Tony Eissa
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

6.  β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling.

Authors:  Massimo Dal Monte; Irene Fornaciari; Grazie Paola Nicchia; Maria Svelto; Giovanni Casini; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-06       Impact factor: 3.000

7.  Role of endogenous and exogenous nitric oxide, carbon monoxide and hydrogen sulfide in HCT116 colon cancer cell proliferation.

Authors:  Gabor Oláh; Katalin Módis; Gabor Törö; Mark R Hellmich; Bartosz Szczesny; Csaba Szabo
Journal:  Biochem Pharmacol       Date:  2017-10-23       Impact factor: 5.858

8.  Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.

Authors:  Julie L Heinecke; Lisa A Ridnour; Robert Y S Cheng; Christopher H Switzer; Michael M Lizardo; Chand Khanna; Sharon A Glynn; S Perwez Hussain; Howard A Young; Stefan Ambs; David A Wink
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

9.  IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients.

Authors:  Ahmed-Amine Zergoun; Abderezak Zebboudj; Sarah Leila Sellam; Nora Kariche; Djamel Djennaoui; Samir Ouraghi; Esma Kerboua; Zine-Charaf Amir-Tidadini; Dalia Chilla; Fatima Asselah; Chafia Touil-Boukoffa; Taha Merghoub; Mehdi Bourouba
Journal:  Tumour Biol       Date:  2015-10-09

Review 10.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.